Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Philadelphia Chromosome-Positive

Interventions

BIOLOGICAL: Blinatumomab
DRUG: dasatinib
DRUG: dexamethasone
DRUG: methotrexate

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]